There are currently 239 clinical trials in Boise, Idaho looking for participants to engage in research studies. Trials are conducted at various facilities, including Saint Alphonsus Cancer Care Center-Boise, Saint Luke's Cancer Institute - Boise, Saint Luke's Mountain States Tumor Institute and Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Research Site, Boise, Idaho
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
NCT06454240
Recruiting
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung funct... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/26/2025
Locations: The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002, Boise, Idaho
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/25/2025
Locations: St. Luke's Children's Endocrinology and Diabetes, Boise, Idaho
Conditions: Type 2 Diabetes
Register for Updates
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
NCT06563102
Recruiting
The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/23/2025
Locations: Research Site, Boise, Idaho
Conditions: Mild Asthma
Register for Updates
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648
Recruiting
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a... Read More
Gender:
FEMALE
Ages:
Between 22 years and 77 years
Trial Updated:
05/23/2025
Locations: Advanced Specialty Research, Boise, Idaho
Conditions: Stress Urinary Incontinence (SUI)
Register for Updates
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/23/2025
Locations: Research Site, Boise, Idaho
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
Recruiting
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/22/2025
Locations: Consultants In Epilepsy and Neurology, Boise, Idaho
Conditions: Focal Onset Seizure
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/22/2025
Locations: Northwest Clinical Trials, Boise, Idaho
Conditions: Alzheimer Disease
Register for Updates
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Boise VA Medical Center, Boise, Idaho
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/22/2025
Locations: Saint Alphonsus Regional Medical Center- Cancer Care Center, Boise, Idaho
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/22/2025
Locations: Northwest Clinical Trials, Boise, Idaho
Conditions: Episodic Migraine
Register for Updates